Beijing Huili Technology

Beijing Huili Technology is a clinical-stage biotechnology company based in China that specializes in the development of high-performance microsphere drug delivery systems. The company utilizes its proprietary Uniform Microsphere technology platform to create long-acting injectable formulations for chronic diseases, addressing challenges such as inconsistent drug release and manufacturing scalability. Their current pipeline focuses on metabolic disorders, central nervous system diseases, and endocrine conditions, with lead programs including long-acting versions of exenatide and risperidone. By reducing dosing frequency and improving pharmacokinetic profiles, Huili Technology aims to significantly enhance patient compliance and therapeutic efficacy. The company is backed by prominent venture capital firms, including Legend Capital and Matrix Partners China, and operates out of the Zhongguancun Life Science Park in Beijing.